Gallbladder cancer: adjuvant CRT extends survival in node-positive disease

  • Sci Rep

  • von Jim Kling
  • Studien – kurz & knapp
Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten. Der Zugang zum gesamten Inhalt dieser Seite ist nur Angehörigen medizinischer Fachkreise vorbehalten.

Takeaway

  • Adjuvant chemoradiotherapy (CRT) is associated with reduced recurrence and better survival in lymph node-positive gallbladder cancer.
  • No benefit observed in node-negative patients.

Why this matters

  • Previous studies have combined gallbladder and extra- and intrahepatic bile duct cancer and patients undergoing surgery with noncurative intent.

Study design

  • Retrospective analysis of patients with gallbladder cancer who underwent resection with curative intent (n=151).
  • Funding: National Cancer Center.

Key results

  • 64.9% received adjuvant therapy (25.8% chemotherapy, 39.1% CRT) and 35.1% received no adjuvant therapy.
  • In T2-3N0M0 stage disease, adjuvant therapy had no effect on 5-year locoregional recurrence-free survival (LRFS), recurrence-free survival (RFS), or OS.
  • In patients with T2-3N1-2M0 disease, adjuvant CRT was associated with better outcomes than no adjuvant therapy or chemotherapy:
    • Locoregional recurrence (11.4%, 78.1%, and 68.4%, respectively; P<.001>
    • Distant recurrence (42.8%, 73.9%, and 66.7%, respectively; P=.044).
    • LRFS (82.1%, 19.0%, and 26.8%; P<.05>
    • RFS (53.3%, 11.6%, and 16.7%; P<.05>
    • OS (64.0%, 4.3%, and 22.7%; P<.05>

Limitations

  • Retrospective analysis.
  • Single institution.
  • Korean population.